Ken Griffin Bicycle Therapeutics PLC Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	BUY	$13.81 - $27.5 $6,905 - $13,750	500 Added 8.2%	6,600 $92,000
Q3 2024 Nov 14, 2024	BUY	$19.58 - $27.24 $70,488 - $98,064	3,600 Added 144.0%	6,100 $138,000
Q2 2024 Aug 14, 2024	SELL	$20.02 - $24.69 $182,182 - $224,679	-9,100 Reduced 78.45%	2,500 $50,000
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $75,375 - $117,450	-4,500 Reduced 27.95%	11,600 $288,000
Q4 2023 Feb 14, 2024	SELL	$13.29 - $22.2 $184,731 - $308,580	-13,900 Reduced 46.33%	16,100 $291,000
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $43,780 - $57,750	2,200 Added 7.91%	30,000 $602,000
Q2 2023 Aug 14, 2023	BUY	$18.95 - $28.67 $15,160 - $22,936	800 Added 2.96%	27,800 $709,000
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $96,096 - $150,576	4,800 Added 21.62%	27,000 $574,000
Q4 2022 Feb 14, 2023	BUY	$20.37 - $32.9 $452,214 - $730,380	22,200 New	22,200 $657,000

104

42.9M

12.1K

17.4K

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $329M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.